Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 17/20 | 1.00 |
| ▸ | MDM4 | O15151 | 13/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.84 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.73 |
| ▸ | RPA1 | P27694 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18618681 | 0.87 | MDM2 (0.77) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18619683 | 0.85 | MDM2 (0.74) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18619948 | 0.84 | MDM2 (0.73) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL19406702 | 0.84 | MDM2 (0.72) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18618676 | 0.84 | MDM2 (0.72) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL19406744 | 0.83 | MDM2 (0.71) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18619751 | 0.83 | MDM2 (0.71) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18618628 | 0.83 | MDM2 (0.70) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL18619681 | 0.83 | MDM2 (0.70) | MDM2MDM4TP53PCSK9 | |
| SCHEMBL19406552 | 0.83 | MDM2 (0.76) | MDM2MDM4TP53PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 829 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025098488-A1 | DRUG UPREGULATING P53 PROTEIN EXPRESSION OR ACTIVATING P53 FUNCTION AND DNA ALKYLATING AGENT USED IN COMBINATION FOR TREATING CANCER | 深圳艾欣达伟医药科技有限公司 | 2025-05-15 | — | — | WO | claimed |
| WO-2025061648-A1 | TARGETING THE C-MYC/MDM2 PATHWAY FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-27 | — | — | WO | claimed |
| CN-119110805-A | Stapled peptide-antibody conjugate (SPAC) and uses thereof | 利帝卡治疗股份有限公司 | 2024-12-10 | — | — | CN | claimed |
| EP-4444736-A2 | STAPLED PEPTIDE-ANTIBODY CONJUGATES (SPACS) AND USES THEREOF | Lytica Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-09-05 | — | — | US | claimed |
| US-20240226088-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2024-07-11 | — | — | US | claimed |
| US-20240075099-A1 | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | DANA-FARBER CANCER INSTITUTE, INC. | 2024-03-07 | — | — | US | claimed |
| EP-4301875-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-01-10 | — | — | EP | claimed |
| CN-117295825-A | Biomarkers for the treatment of cancer using MDM2 antagonists | 大冢制药株式会社 | 2023-12-26 | — | — | CN | claimed |
| EP-4081801-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-11-02 | — | — | EP | claimed |
| CN-115252786-A | Dosage and regimen for HDM2-p53 interaction inhibitors | 诺华股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-115066614-A | Biomarkers for treating cancer using MDM2 antagonists | 大冢制药株式会社 | 2022-09-16 | — | — | CN | claimed |
| WO-2022185260-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-09-09 | — | — | WO | claimed |
| WO-2022175402-A1 | QUINUCLIDINE-3-ONE DERIVATIVES | APREA THERAPEUTICS AB (SE) | 2022-08-25 | — | — | WO | claimed |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AROG PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | claimed |
| US-20220071970-A1 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | APREA THERAPEUTICS AB (SE) | 2022-03-10 | — | — | US | claimed |
| WO-2022043930-A2 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-03 | — | — | WO | claimed |
| US-20220031697-A1 | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors | NOVARTIS PHARMA AG (CH) | 2022-02-03 | — | — | US | claimed |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345322-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | MDM2 1345/4885MDM4 2926/4885TP53 5/4885 |
| US-20240293364-A1 | BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS | MSH2, MRE11, RAD50 | MDM2 6/4885MDM4 66/4885TP53 18/4885 |
| US-20220071970-A1 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | NQO2, MKI67, NQO1 | MDM2 1278/4885MDM4 997/4885TP53 4/4885 |
| US-20220031694-A1 | COMBINATION PRODUCT OF BCL-2 INHIBITOR AND MDM2 INHIBITOR AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF DISEASES | BCL2, BCL2L2, BCL2L1 | MDM2 5/4885MDM4 22/4885TP53 9/4885 |
| US-20240075099-A1 | COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS | TP53, DDX21, MDM2 | MDM2 3/4885MDM4 15/4885TP53 1/4885 |
| US-20220133710-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | MDM2 1345/4885MDM4 2926/4885TP53 5/4885 |
| US-20240226088-A1 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CCAR2, BAX, DUSP22 | MDM2 1345/4885MDM4 2926/4885TP53 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.